Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Operating Income Loss of -$1.28 million for the year ending 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -70.6% in Operating Income Loss from 2023 to 2024.
- This data is from Apimeds Pharmaceuticals US, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2023 to 2024 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$271.7 thousand | Q2 2024: -$427.8 thousand | Q3 2024: -$300.0 thousand | Q1 2025: -$364.4 thousand | Q2 2025: -$2.66 million | Q3 2025: -$1.84 million.
- Historical annual values: Fiscal year 2024: -$1.28 million | Fiscal year 2023: -$747.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: